BioCentury | Oct 6, 2017
Clinical News

Melior begins Phase IIb trial for Type II diabetes candidate MLR-1023

...insulin, insulin sensitivities, lipid profile and body weight. MLR-1023 is a Lyn kinase (LYN) activator. Bukwang Pharmaceutical Co. Ltd....
...Phase IIb testing (see BioCentury Dec. 16, 2013 ). Melior Discovery Inc. , Exton, Pa. Bukwang Pharmaceutical Co. Ltd....
...fasting insulin, insulin sensitivities, lipid profile and body weight Status: Phase IIb started Milestone: NA Allison Johnson MLR-1023 Bukwang Pharmaceutical Co. Ltd. Melior...
BioCentury | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

...$4.1 million series A and $8.2 million series B rounds. The series A round included Bukwang Pharmaceutical Co. Ltd....
BioCentury | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

...$4.1 million series A and $8.2 million series B rounds. The series A round included Bukwang Pharmaceutical Co. Ltd....
BioCentury | Mar 15, 2017
Clinical News

Apatinib: Ph III ANGEL started

...Laboratories. Jiangsu Hengrui markets the product in China for gastric cancer. LSK is partnered with Bukwang...
...Korea. Advenchen Laboratories LLC , Moorpark, Calif. LSK BioPharma Inc. , Salt Lake City, Utah Bukwang Pharmaceutical Co. Ltd....
...quality of life (QOL), safety and pharmacokinetics Status: Phase III started Milestone: NA Julian Zhu YN986D1 Advenchen Laboratories LLC Bukwang Pharmaceutical Co. Ltd. Jiangsu...
BioCentury | Jun 27, 2016
Clinical News

MLR-1023: Phase IIa data

...generally well tolerated. Data were presented at the American Diabetes Association meeting in New Orleans. Bukwang...
...through Phase IIb testing (see BioCentury, Dec. 16, 2013). Melior Discovery Inc. , Exton, Pa. Bukwang Pharmaceutical Co. Ltd....
BioCentury | May 16, 2016
Financial News

Acer Therapeutics completes venture financing

...Endocrine/Metabolic Date completed: 2016-05-09 Type: Venture financing Raised: $8.2 million Investors: TVM Life Science Ventures; Bukwang Pharmaceutical Co. Ltd. WIR...
BioCentury | Mar 21, 2016
Finance

Multiples in Korea

...companies after this initial government investment is KOSDAQ." The firm has a deal with Korea's Bukwang Pharmaceutical Co. Ltd....
BioCentury | Apr 13, 2015
Clinical News

MLR-1023: Phase IIa started

...200 mg oral MLR-1023 once or twice daily for 4 weeks in about 120 patients. Bukwang Pharmaceutical Co. Ltd....
BioCentury | Nov 24, 2014
Company News

Melior, Bukwang deal

...Melior received the first milestone payment under a 2013 deal granting Bukwang exclusive rights to commercialize...
...payment is not disclosed (see BioCentury, Dec. 16, 2013). Melior Discovery Inc. , Exton, Pa. Bukwang Pharmaceutical Co. Ltd....
BioCentury | Oct 13, 2014
Financial News

TVM Capital financial update

...Ind.). Also participating were Business Development Bank of Canada; Minnesota Life Insurance; CD Venture; FondAction; Bukwang Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 41
BioCentury | Oct 6, 2017
Clinical News

Melior begins Phase IIb trial for Type II diabetes candidate MLR-1023

...insulin, insulin sensitivities, lipid profile and body weight. MLR-1023 is a Lyn kinase (LYN) activator. Bukwang Pharmaceutical Co. Ltd....
...Phase IIb testing (see BioCentury Dec. 16, 2013 ). Melior Discovery Inc. , Exton, Pa. Bukwang Pharmaceutical Co. Ltd....
...fasting insulin, insulin sensitivities, lipid profile and body weight Status: Phase IIb started Milestone: NA Allison Johnson MLR-1023 Bukwang Pharmaceutical Co. Ltd. Melior...
BioCentury | Jul 7, 2017
Company News

Acer finds public path via Opexa merger

...$4.1 million series A and $8.2 million series B rounds. The series A round included Bukwang Pharmaceutical Co. Ltd....
BioCentury | Jul 3, 2017
Company News

Acer finds public path via Opexa merger

...$4.1 million series A and $8.2 million series B rounds. The series A round included Bukwang Pharmaceutical Co. Ltd....
BioCentury | Mar 15, 2017
Clinical News

Apatinib: Ph III ANGEL started

...Laboratories. Jiangsu Hengrui markets the product in China for gastric cancer. LSK is partnered with Bukwang...
...Korea. Advenchen Laboratories LLC , Moorpark, Calif. LSK BioPharma Inc. , Salt Lake City, Utah Bukwang Pharmaceutical Co. Ltd....
...quality of life (QOL), safety and pharmacokinetics Status: Phase III started Milestone: NA Julian Zhu YN986D1 Advenchen Laboratories LLC Bukwang Pharmaceutical Co. Ltd. Jiangsu...
BioCentury | Jun 27, 2016
Clinical News

MLR-1023: Phase IIa data

...generally well tolerated. Data were presented at the American Diabetes Association meeting in New Orleans. Bukwang...
...through Phase IIb testing (see BioCentury, Dec. 16, 2013). Melior Discovery Inc. , Exton, Pa. Bukwang Pharmaceutical Co. Ltd....
BioCentury | May 16, 2016
Financial News

Acer Therapeutics completes venture financing

...Endocrine/Metabolic Date completed: 2016-05-09 Type: Venture financing Raised: $8.2 million Investors: TVM Life Science Ventures; Bukwang Pharmaceutical Co. Ltd. WIR...
BioCentury | Mar 21, 2016
Finance

Multiples in Korea

...companies after this initial government investment is KOSDAQ." The firm has a deal with Korea's Bukwang Pharmaceutical Co. Ltd....
BioCentury | Apr 13, 2015
Clinical News

MLR-1023: Phase IIa started

...200 mg oral MLR-1023 once or twice daily for 4 weeks in about 120 patients. Bukwang Pharmaceutical Co. Ltd....
BioCentury | Nov 24, 2014
Company News

Melior, Bukwang deal

...Melior received the first milestone payment under a 2013 deal granting Bukwang exclusive rights to commercialize...
...payment is not disclosed (see BioCentury, Dec. 16, 2013). Melior Discovery Inc. , Exton, Pa. Bukwang Pharmaceutical Co. Ltd....
BioCentury | Oct 13, 2014
Financial News

TVM Capital financial update

...Ind.). Also participating were Business Development Bank of Canada; Minnesota Life Insurance; CD Venture; FondAction; Bukwang Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 41